These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10242132)

  • 1. Use of generics will mean cost savings.
    Nelson G
    Internist; 1979 May; 20(4):6-8. PubMed ID: 10242132
    [No Abstract]   [Full Text] [Related]  

  • 2. Generic vs. brand name drugs--quality, not cost, is key issue.
    Stetler CJ
    Internist; 1979 May; 20(4):9-10, 12. PubMed ID: 10242133
    [No Abstract]   [Full Text] [Related]  

  • 3. Another round over generics.
    Kosterlitz J
    Natl J (Wash); 1985 Oct; 17(42):2373, 2376. PubMed ID: 10274030
    [No Abstract]   [Full Text] [Related]  

  • 4. How to pay less for prescription drugs.
    Consum Rep; 1975 Jan; 40(1):48-53. PubMed ID: 1244036
    [No Abstract]   [Full Text] [Related]  

  • 5. Generics still a favorite Rx for savings.
    Wagner M
    Mod Healthc; 1990 May; 20(21):26-8, 30, 32-3. PubMed ID: 10104890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic consequences of the maximum allowable cost program to the entire profession of pharmacy.
    Paul SH
    Med Mark Media; 1979 Aug; 14(8):19-26. PubMed ID: 10243270
    [No Abstract]   [Full Text] [Related]  

  • 7. Generic vs. brand name drugs--defining and enforcing standards.
    Lasagna LC
    Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827
    [No Abstract]   [Full Text] [Related]  

  • 8. The Society's position on generics.
    Internist; 1979 May; 20(4):16. PubMed ID: 10242130
    [No Abstract]   [Full Text] [Related]  

  • 9. Doctors are pivotal to prescription struggle.
    Chapman S
    Leg Aspects Med Pract; 1979 Mar; 7(3):42-4. PubMed ID: 423688
    [No Abstract]   [Full Text] [Related]  

  • 10. States moving to allow generic substitution.
    Internist; 1979 May; 20(4):12-3. PubMed ID: 10242129
    [No Abstract]   [Full Text] [Related]  

  • 11. Additional generics on the market.
    FDA Drug Bull; 1986 Nov; 16(2):14-5. PubMed ID: 3817341
    [No Abstract]   [Full Text] [Related]  

  • 12. Implications of the Lannett and Pharmadyne decisions.
    Vetrano AJ
    Am J Hosp Pharm; 1980 Apr; 37(4):537-40. PubMed ID: 7377217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generics, private-labels may shake stagnant cephalosporin prices.
    Brightbill TC
    Hosp Mater Manage; 1987 Jun; 12(6):3-7. PubMed ID: 10283111
    [No Abstract]   [Full Text] [Related]  

  • 14. MAC--a cutting tool for federal reimbursements on prescription drugs?
    Hirsh HL
    J Leg Med (N Y); 1976 Feb; 4(2):31-3. PubMed ID: 1082483
    [No Abstract]   [Full Text] [Related]  

  • 15. Generic drug purchasing.
    Mehl B
    Hosp Pharm; 1988 Feb; 23(2):162-4 contd. PubMed ID: 10286432
    [No Abstract]   [Full Text] [Related]  

  • 16. Knowledge is power: legislative control of drug industry trade secrets.
    O'Reilly JT
    Spec Law Dig Health Care (Mon); 1987 May; 8(15):7-31. PubMed ID: 10281981
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacy: how cost-effective are generics?
    Wolfe H
    Hospitals; 1973 May; 47(9):100-8. PubMed ID: 4702078
    [No Abstract]   [Full Text] [Related]  

  • 18. The Maximum Allowable Cost program--some marketing consequences.
    Gosselin RA
    Med Mark Media; 1978 Feb; 13(2):19-20, 22, 24 passim. PubMed ID: 10306394
    [No Abstract]   [Full Text] [Related]  

  • 19. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 20. Plugs for drugs.
    Masson A; Rubin PH
    Regulation; 1986; 10(1):37-43, 53. PubMed ID: 10280556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.